FDA- CLOSELY MONITORING THE RISK OF NEOPLASIA, INCLUDING MALIGNANCY, IN OTHER SIMILAR AAV VECTOR-BASED GENE THERAPY PROGRAMS

1

FDA- CLOSELY MONITORING THE RISK OF NEOPLASIA, INCLUDING MALIGNANCY, IN OTHER SIMILAR AAV VECTOR-BASED GENE THERAPY PROGRAMS

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)